AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31216218 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated women (unexposed cohort)
Number of subjects: 1203
Study 31216297 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment
Number of subjects: 0
Study 31216297 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 0
Study 31216297 — intervention group
Group type: COMPARATOR
Intervention: Laser-Doppler flowmetry
Number of subjects: 0
Study 31216376 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-acquired respiratory viral infections (CARVs) detected in 156 patient visits (74% enterovirus/rhinovirus)
Number of subjects: 61
Study 31216376 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival rates
Number of subjects: 61
Study 31216376 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchiolitis obliterans syndrome incidence
Number of subjects: 61
Study 31216376 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary endpoint met
Number of subjects: 61
Study 31217161 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplo-identical transplant with posttransplant cyclophosphamide (haplo)
Number of subjects: 307
Study 31217161 — intervention group
Group type: COMPARATOR
Intervention: Haplo-cord transplant supported by third-party CD34 cells (haplo-cord)
Number of subjects: 307
Study 31217320 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle, environmental and occupational factors assessment through a standardized questionnaire and saliva sample collection.
Number of subjects: 0
Study 31217320 — intervention group
Group type: COMPARATOR
Intervention: Control group matched by sex, age, and district of residence.
Number of subjects: 0
Study 31217479 — intervention group
Group type: EXPERIMENTAL
Intervention: TSR-011 40 mg every 8 hours (Q8h)
Number of subjects: 14
Study 31217479 — intervention group
Group type: EXPERIMENTAL
Intervention: TSR-011 320- and 480-mg Q24h doses
Number of subjects: 14
Study 31217479 — intervention group
Group type: EXPERIMENTAL
Intervention: TSR-011 40 mg Q8h
Number of subjects: 14
Study 31217479 — intervention group
Group type: EXPERIMENTAL
Intervention: TSR-011
Number of subjects: 14
Study 31217818 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly irinotecan at 80 mg/m² in combination with capecitabine-based radiotherapy (50 Gy/25 fractions)
Number of subjects: 52
Study 31217992 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based heart failure tool (education, symptom monitoring, diuretic titration)
Number of subjects: 172
Study 31217993 — intervention group
Group type: EXPERIMENTAL
Intervention: HART PAD panel (clinical variable: history of hypertension; biomarkers: midkine, kidney injury molecule-1, interleukin-23, follicle-stimulating hormone, angiopoietin-1, eotaxin-1)
Number of subjects: 354
Study 31217997 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher aortic stiffness (PWV >8.7 m/s)
Number of subjects: 125
Study 31218003 — intervention group
Group type: EXPERIMENTAL
Intervention: Toronto Aortic Stenosis Quality of Life Questionnaire (TASQ)
Number of subjects: 290
Study 31218003 — intervention group
Group type: COMPARATOR
Intervention: Kansas City Cardiomyopathy Questionnaire
Number of subjects: 290
Study 31218003 — intervention group
Group type: COMPARATOR
Intervention: Short Form-12 questionnaire
Number of subjects: 290
Study 31218013 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated initiation of renal replacement therapy (RRT) within 12 hours of meeting eligibility criteria
Number of subjects: 2866
Study 31218013 — intervention group
Group type: COMPARATOR
Intervention: Standard initiation of renal replacement therapy (RRT) based on clinician judgment or urgent complications
Number of subjects: 2866
Study 31218013 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated initiation of RRT
Number of subjects: 2866
Study 31218013 — intervention group
Group type: COMPARATOR
Intervention: Standard initiation of RRT
Number of subjects: 2866
Study 31218482 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboelastography, oxidized LDL β2-glycoprotein complex (AtherOx), oxidized-LDL, lipid profile, and urine for 11-dehydrothromboxane B
Number of subjects: 134
Study 31218680 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-HIT (12 weeks of virtually supervised home-based high-intensity interval training)
Number of subjects: 32
Study 31218680 — intervention group
Group type: COMPARATOR
Intervention: Home-based MICT (moderate-intensity continuous training)
Number of subjects: 32
Study 31218680 — intervention group
Group type: COMPARATOR
Intervention: Laboratory-based HIT
Number of subjects: 32
Study 31218780 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural language processing (NLP) software application for coding clinical text documentation of overdose
Number of subjects: 0
Study 31219045 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based mindfulness-based intervention (MBI)
Number of subjects: 149
Study 31219185 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus-specific T cells (VSTs)
Number of subjects: 12
Study 31219185 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study 31219594 — intervention group
Group type: EXPERIMENTAL
Intervention: ICF core set and ICF-based questionnaire (Cochin Scleroderma ICF-65 questionnaire) assessing activities and participation in patients with SSc.
Number of subjects: 28
Study 31219619 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglossal nerve stimulation
Number of subjects: 20
Study 31219975 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (R-CAR-cohort)
Number of subjects: 10
Study 31219975 — intervention group
Group type: COMPARATOR
Intervention: Intensive combined chemotherapy (C-CAR-cohort)
Number of subjects: 10
Study 31220220 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir for 8 weeks
Number of subjects: 27
Study 31220220 — intervention group
Group type: COMPARATOR
Intervention: Historical control (pegylated-interferon/ribavirin)
Number of subjects: 27
Study 31220258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin (loading dose followed by constant infusion)
Number of subjects: 8
Study 31220258 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (standard dosing regimen)
Number of subjects: 8
Study 31220276 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (sc) prolonged suppressive antibiotic therapy (PSAT) using ertapenem, ceftriaxone, or ceftazidime
Number of subjects: 10
Study 31220276 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (sc) PSAT
Number of subjects: 10
Study 31220291 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement
Number of subjects: 183
Study 31220349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir (weight-based doses: 33.75 mg/150 mg for weights <17 kg or 45 mg/200 mg for weights ≥17 kg) for 12 weeks
Number of subjects: 34
Study 31220349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir
Number of subjects: 34
Study 31220357 — intervention group
Group type: EXPERIMENTAL
Intervention: VCTE (vibration-controlled transient elastography)
Number of subjects: 139
Study 31220357 — intervention group
Group type: EXPERIMENTAL
Intervention: APRI (aspartate aminotransferase-to-platelet ratio index)
Number of subjects: 139
Study 31220357 — intervention group
Group type: EXPERIMENTAL
Intervention: FIB-4 index
Number of subjects: 139
Study 31220357 — intervention group
Group type: EXPERIMENTAL
Intervention: VCTE
Number of subjects: 139
Study 31220357 — intervention group
Group type: EXPERIMENTAL
Intervention: APRI or FIB-4 jointly with VCTE
Number of subjects: 139
Study 31220387 — intervention group
Group type: EXPERIMENTAL
Intervention: ADD-RS/ME
Number of subjects: 1030
Study 31220387 — intervention group
Group type: EXPERIMENTAL
Intervention: ADD-RS/aCRs
Number of subjects: 1030
Study 31220387 — intervention group
Group type: COMPARATOR
Intervention: CR (per se) for ME
Number of subjects: 1030
Study 31220387 — intervention group
Group type: COMPARATOR
Intervention: CR (per se) for aCRs
Number of subjects: 1030
Study 31220387 — intervention group
Group type: EXPERIMENTAL
Intervention: ADD-RS/ME rule-out
Number of subjects: 1030
Study 31220387 — intervention group
Group type: EXPERIMENTAL
Intervention: ADD-RS/aCRs rule-out
Number of subjects: 1030
Study 31220400 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage radiotherapy (SRT) with pre-SRT PSA level <0.5 ng/mL
Number of subjects: 555
Study 31220400 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed SRT with PSA level ≥0.5 ng/mL
Number of subjects: 555
Study 31220400 — intervention group
Group type: EXPERIMENTAL
Intervention: Early SRT at PSA level <0.5 ng/mL
Number of subjects: 555
Study 31220400 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT alone in patients with PSA level ≥0.5 ng/mL and higher-risk features
Number of subjects: 555
Study 31220413 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral inferior turbinate reduction (BITR) with endoscopic sinus surgery (ESS)
Number of subjects: 571
Study 31220413 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sinus surgery (ESS) alone
Number of subjects: 571
Study 31220623 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid saline infusion
Number of subjects: 50
Study 31220623 — intervention group
Group type: COMPARATOR
Intervention: Exercise (semisupine ergometer at 25%, 50%, and 75% of peak VO2)
Number of subjects: 50
Study 31220640 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS with nCLE
Number of subjects: 144
Study 31220640 — intervention group
Group type: COMPARATOR
Intervention: Measurement of CEA and cytology analysis
Number of subjects: 144
Study 31220640 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of postprocedure acute pancreatitis
Number of subjects: 144
Study 31220806 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab 100 mg SC
Number of subjects: 0
Study 31220806 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 31220942 — intervention group
Group type: EXPERIMENTAL
Intervention: S100a9 neutralizing antibody administration
Number of subjects: 0
Study 31220942 — intervention group
Group type: EXPERIMENTAL
Intervention: Knockout of S100a9
Number of subjects: 0
Study 31220942 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic overexpression of S100a9
Number of subjects: 0
Study 31220942 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic serum S100a8/a9 levels measurement
Number of subjects: 0
Study 31221129 — intervention group
Group type: EXPERIMENTAL
Intervention: MIND questionnaire
Number of subjects: 128
Study 31221215 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual community of practice (vCoP) for primary care professionals
Number of subjects: 12
Study 31221542 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept plus FOLFIRI
Number of subjects: 779
Study 31221711 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-Based, Patient-Centered Diabetes Care System
Number of subjects: 0
Study 31221711 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 31221778 — intervention group
Group type: EXPERIMENTAL
Intervention: New drugs
Number of subjects: 2332
Study 31221778 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of extramedullary disease
Number of subjects: 2332
Study 31221874 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicentric longitudinal observational study of children with ASD
Number of subjects: 1000
Study 31221874 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination and battery of clinical tools (Autism Diagnostic Observation Schedule, revised Autism Diagnostic Interview, measures of intellectual functioning, behavioral and developmental measurements)
Number of subjects: 1000
Study 31221874 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments at 18 months, 3 years, 4.5 years, and 6 years after baseline examination
Number of subjects: 1000
Study 31221874 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported questionnaires completed by parents
Number of subjects: 1000
Study 31221878 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare-associated or nosocomial infection (HAI) cases
Number of subjects: 0
Study 31221878 — intervention group
Group type: COMPARATOR
Intervention: Non-HAI cases (control group)
Number of subjects: 0
Study 31222633 — intervention group
Group type: EXPERIMENTAL
Intervention: Rockall scores ≥6 group
Number of subjects: 140
Study 31222633 — intervention group
Group type: COMPARATOR
Intervention: Rockall scores <6 group
Number of subjects: 140
Study 31222633 — intervention group
Group type: EXPERIMENTAL
Intervention: Rockall scores ≥6 group (per-protocol analysis)
Number of subjects: 140
Study 31222633 — intervention group
Group type: COMPARATOR
Intervention: Rockall scores <6 group (per-protocol analysis)
Number of subjects: 140
Study 31222663 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical group (CKD patients with psychosocial adjustment or mental health problems)
Number of subjects: 166
Study 31222714 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron
Number of subjects: 1514
Study 31222714 — intervention group
Group type: COMPARATOR
Intervention: Antimuscarinics
Number of subjects: 1514
Study 31222720 — intervention group
Group type: EXPERIMENTAL
Intervention: G-estimation using a quadratic approximation approach inspired by iteratively reweighted least squares.
Number of subjects: 0
Study 31222722 — intervention group
Group type: EXPERIMENTAL
Intervention: CUSP9-LD (low-dose CUSP9) combined with Bcl-2/Bcl-xL inhibitor ABT263
Number of subjects: 0
Study 31222722 — intervention group
Group type: COMPARATOR
Intervention: CUSP9-LD
Number of subjects: 0
Study 31222783 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin for 12 weeks (genotype 2) or 24 weeks (genotype 3); Sofosbuvir dosage: 150 mg for patients aged 3 to <6 years weighing <17 kg, 200 mg for patients aged 3 to <6 years weighing ≥17 kg and all patients aged 6 to <12 years; Ribavirin dosing based on weight (up to 1,400 mg/day, two divided doses).
Number of subjects: 54
Study 31222783 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin
Number of subjects: 54
Study 31223191 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AER)
Number of subjects: 16
Study 31223191 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise (ECC)
Number of subjects: 16
Study 31225429 — intervention group
Group type: EXPERIMENTAL
Intervention: DMARD withdrawal
Number of subjects: 13
Study 31225583 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured Total Energy Expenditure (TEE)
Number of subjects: 21
Study 31225583 — intervention group
Group type: COMPARATOR
Intervention: Energy recommendation of 25 kcal/kg
Number of subjects: 21
Study 31225583 — intervention group
Group type: COMPARATOR
Intervention: Dietary Reference Intakes (DRIs)
Number of subjects: 21
Study 31225583 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Level (PAL)
Number of subjects: 21
Study 31225583 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypermetabolism defined as REE > 110% of predicted
Number of subjects: 21
Study 31225610 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytical treatment interruption (ATI)
Number of subjects: 9
Study 31225610 — intervention group
Group type: EXPERIMENTAL
Intervention: Resumption of ART after confirmed viral rebound
Number of subjects: 9
Study 31225610 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline factors
Number of subjects: 9
Study 31225870 — intervention group
Group type: EXPERIMENTAL
Intervention: Atg7 knockdown in 3T3-L1 adipocytes
Number of subjects: 183
Study 31225870 — intervention group
Group type: COMPARATOR
Intervention: High-calorie diet in mice
Number of subjects: 183
Study 31225870 — intervention group
Group type: COMPARATOR
Intervention: Human subcutaneous adipose tissue ATG7 mRNA expression
Number of subjects: 183
Study 31225870 — intervention group
Group type: COMPARATOR
Intervention: Single nucleotide polymorphism Rs2606729 in ATG7
Number of subjects: 183
Study 31225872 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) treatment of MCF7 cells
Number of subjects: 6
Study 31225872 — intervention group
Group type: COMPARATOR
Intervention: GR antagonist RU486
Number of subjects: 6
Study 31225872 — intervention group
Group type: COMPARATOR
Intervention: Actinomycin
Number of subjects: 6
Study 31225872 — intervention group
Group type: COMPARATOR
Intervention: Defective 501H GR mutant
Number of subjects: 6
Study 31226260 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 46
Study 31226260 — intervention group
Group type: COMPARATOR
Intervention: Non-ADHD
Number of subjects: 46
Study 31226260 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD participants
Number of subjects: 46
Study 31226985 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 2500
Study 31226985 — intervention group
Group type: COMPARATOR
Intervention: Other approved therapies
Number of subjects: 2500
Study 31227534 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly-interventional spasticity management (including SDR, ITB, anti-spasticity injections and medications)
Number of subjects: 0
Study 31227534 — intervention group
Group type: COMPARATOR
Intervention: Minimally-interventional spasticity management (no SDR)
Number of subjects: 0
Study 31227585 — intervention group
Group type: COMPARATOR
Intervention: Family-based lifestyle and psycho-educational intervention program (control intervention)
Number of subjects: 116
Study 31227585 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise in addition to the family-based lifestyle and psycho-educational intervention program
Number of subjects: 116
Study 31228053 — intervention group
Group type: EXPERIMENTAL
Intervention: No-cost diagnostic colonoscopy arranged through telephonic navigation after abnormal FIT results.
Number of subjects: 689
Study 31228053 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for not completing follow-up colonoscopy among non-completers.
Number of subjects: 689
Study 31228053 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous colonoscopy completion status among non-completers.
Number of subjects: 689
Study 31228053 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for non-completion without reported barriers.
Number of subjects: 689
Study 31228090 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 607
Study 31228090 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 607
Study 31228090 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine
Number of subjects: 607
Study 31228090 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide (both doses)
Number of subjects: 607
Study 31228090 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 607
Study 31228100 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg once daily
Number of subjects: 1305
Study 31228100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1305
Study 31228100 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg biweekly
Number of subjects: 1305
Study 31228101 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 341
Study 31228101 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg no-load
Number of subjects: 341
Study 31228101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study 31228101 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg or 150 mg no-load
Number of subjects: 341
Study 31228101 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg (after dose escalation)
Number of subjects: 341
Study 31228176 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital physiotherapy (PT)
Number of subjects: 66
Study 31228176 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 66
Study 31228177 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART4MD app on a data-enabled computer tablet, used daily at home.
Number of subjects: 1200
Study 31228177 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 1200
Study 31228214 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic hepatitis patients with ASCA levels ≥34 IU/mL
Number of subjects: 0
Study 31228214 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic hepatitis patients
Number of subjects: 0
Study 31228214 — intervention group
Group type: COMPARATOR
Intervention: Alcohol use disorder patients
Number of subjects: 0
Study 31228214 — intervention group
Group type: COMPARATOR
Intervention: Nonalcoholic controls
Number of subjects: 0
Study 31228214 — intervention group
Group type: COMPARATOR
Intervention: Alcoholic hepatitis and alcohol use disorder groups
Number of subjects: 0
Study 31228626 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 10 mg/kg every 2 weeks for 12 months
Number of subjects: 304
Study 31228626 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 304
Study 31228628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ig20Gly infusion at rates of ≥60 mL/h/site
Number of subjects: 0
Study 31228628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ig20Gly infusion
Number of subjects: 0
Study 31228640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis users
Number of subjects: 390
Study 31228640 — intervention group
Group type: COMPARATOR
Intervention: Non-users
Number of subjects: 390
Study 31228943 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation with 250 ml albumin 5% boluses repeated as required to restore PPV to < 15% (Fluid non-Responding Status - FnRS)
Number of subjects: 67
Study 31228943 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse pressure variations (PPV) of ≥15% indicating fluid resuscitation
Number of subjects: 67
Study 31228943 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous blood samples from central venous and pulmonary artery catheters (PAC)
Number of subjects: 67
Study 31228957 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD) for 1 month
Number of subjects: 18
Study 31229394 — intervention group
Group type: EXPERIMENTAL
Intervention: pARC
Number of subjects: 2089
Study 31229394 — intervention group
Group type: COMPARATOR
Intervention: PAS
Number of subjects: 2089
Study 31229429 — intervention group
Group type: EXPERIMENTAL
Intervention: Triton system (Gauss Surgical, Inc)
Number of subjects: 242
Study 31229429 — intervention group
Group type: COMPARATOR
Intervention: Subjective estimated blood loss
Number of subjects: 242